Prevention and treatment of otitis with using nonpathogenic bacterial strains

FIELD: medicine.

SUBSTANCE: nutrient composition contains the nonpathogenic bacterial strain Lactococcus rhamnosus ATCC 53103 or Lactococcus rhamnosus CGMCC 1.3724 able to stimulate a systemic immune response, and the nonpathogenic bacterial strain Micrococcus varians MCV8 or Streptococcus salivarius DSM 13 084 able to have bacteriostatic and bactericidal effect on pathogens related to the onset of otitis, such as Streptococcus pneumoniae, non-typed Haemophilus influenzae and Moraxella catarrhalis The composition contains 104 to 1012 CFU/g of fresh weight of the composition of each strain. The composition additionally contains Streptococcus thermophilus and additionally contains at least one prebiotic in the amount of 0.3 to 6% of composition weight. The composition represents a baby formula or a food additive.

EFFECT: invention provides an effective protection against nasopharyngeal mucosa colonisation with pathogenic bacteria related with the onset of otitis.

7 cl, 1 tbl, 2 ex

 

The technical field to which the invention relates.

The invention concerns the prevention and treatment of inflammation of the middle ear (otitis media), particularly in infants and young children.

Prior art

Respiratory tract infections are very common, especially in infants and young children. For example, in the first year of life the child picks up from three to six such infections. Such infections can be bacterial or viral. Examples of viral respiratory tract infections include the common cold, influenza and respiratory syncytial virus. Examples of bacterial respiratory tract infections include pneumonia and inflammation of the middle ear.

Frequent respiratory tract infections are often associated with inflammation of the middle ear. It is an infection of the middle ear, in which Evstafieva pipe connecting the cavity of the middle ear with the external environment through the mouth, inflamed, and then clogged, trapping bacteria in the middle ear. The cavity of the middle ear is also inflamed, when this fluid accumulates, leading to increased pressure, which the patient perceives as pain due to inability to equalize pressure between the middle ear and the external environment through Evstafieva pipe, as in healthy persons In severe cases, the eardrum may rupture from pressure and skip infected fluid in EXT is nee ear. This is a potentially dangerous situation, which may cause permanent hearing loss if not treated.

50% of children happens at least one episode of acute otitis media in the first year of life, and 35% of children aged one to three years are recurrences of acute otitis media. In turn, this can cause a condition known as exudative otitis media, in which the liquid does not completely out of the middle ear between the recurrence of the infection. If this condition is established for a long time, it may require surgical intervention.

Acute inflammation of the middle ear is clearly linked to the activity of pathogenic bacteria commonly found among microorganisms living in the nasopharyngeal cavity. In quantitative terms, the most important pathogens are Streptococcus pneumoniae (35% of cases), not amenable to typing Haemophilus influenzae (30%) and Moraxella catarrhalis (10% of cases). For this reason, an acute inflammation of the middle ear is usually treated with antibiotics, especially in infants. In fact, antibiotics are prescribed to treat inflammation of the middle ear more often than any other disease in infancy. This inevitably led to the emergence of resistance to commonly prescribed antibiotics in bacterial strains that are associated with inflammation of the middle ear. For example the EP, it is believed that at least 20% of strains of S. pneumoniae resistant to penicillin and cephalosporins. Similarly, at least 30% of strains of N. influenzae and most strains of M. catarrhalis have any resistance to antibiotics. Such frequent destination, at least partly, due to the fact that infants and young children experience pain, they react prolonged cry, parents and health workers are trying to avoid. Therefore, there is a clear need for alternative ways to reduce the occurrence of this painful and potentially serious illness in infants and young children.

Various alternative methods of treatment has already been proposed. For example, in WO 97/17089 for the prevention of inflammation of the middle ear is proposed to use the so-called immune milk product. This product contains the immunoglobulins of the IgG type against otitis obtained from cow colostrum, in addition to passive immune protection.

It was also suggested various bacterial strains for the prevention/treatment of inflammation of the middle ear. In a recent clinical trial for children with acute middle ear inflammation was sprayed in the nose inhibitor α-hemolytic streptococci. Used strains of Streptococcus mitis, Streptococcus sanguis and Streptococcus oralis. After this treatment, the children had fewer episodes of Ostrog is inflammation of the middle ear (Roos et al. Effect of recolonisation with “interfering alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ 322: 210-212). However, bacterial strains used in this trial are recognized human pathogens involved in diseases such as endocarditis and pulmonary infections.

In WO 2004/072272 it is proposed to use a specific strain of Streptococcus salivarius in the prevention and treatment of inflammation of the middle ear. It is argued that this strain is the producer of bacteriocin and is not pathogenic. It can be applied to the nose, by inhalation through the mouth or in the form of pellets and capsules. Preferably the strain is applied after primary treatment with antibiotics or other antimicrobial agents.

In WO 2006/007526 described a study of 81 infants in Finland, which compared the incidence of otitis media in infants who received formula combination of Lactobacillus rhamnosus and Bifidobacterium lactis, with a control group not treated with probiotics. It was found that the addition of these probiotics have a long history of use in food products for humans, reduced the risk of early acute inflammation of the middle ear compared with the group without such additions. This effect was associated with an overall reduction in the number of infections treated in an additive group, and assume that e is the effect caused by systemic immune stimulating effects of these strains.

From the foregoing it is seen that a need exists for an effective method of prevention and treatment of acute inflammation of the middle ear, which would not depend on the use of antibiotics and which would be convenient and safe to use.

The invention

The authors of the present invention unexpectedly found that when the prevention and treatment of inflammation of the middle ear is particularly effective joint introduction bacterial strains with complementary properties.

Accordingly, in the first aspect, the present invention provides a composition suitable for the prevention and treatment of inflammation of the middle ear, which include non-pathogenic bacterial strain capable of stimulating a systemic immune response, non-pathogenic bacterial strain capable of exerting a bacteriostatic effect on the pathogens associated with the occurrence of inflammation of the middle ear, and non-pathogenic bacterial strain capable of exerting a bactericidal effect on pathogens associated with the occurrence of inflammation of the middle ear.

In a second aspect the present invention provides for the application of non-pathogenic bacterial strain capable of stimulating a systemic immune response, non-pathogenic bacterial strain capable of exerting a bacteriostatic effect on pathogens SV is related to the occurrence of inflammation of the middle ear, and non-pathogenic bacterial strain capable of exerting a bactericidal effect on pathogens associated with the occurrence of inflammation of the middle ear, in the manufacture of compositions for the prevention and treatment of inflammation of the middle ear.

The invention also extends to a method for the prevention and treatment of inflammation of the middle ear, including the introduction to the needy in the individual a therapeutic amount of non-pathogenic bacterial strain capable of stimulating a systemic immune response, non-pathogenic bacterial strain capable of exerting a bacteriostatic effect on the pathogens associated with the occurrence of inflammation of the middle ear, and non-pathogenic bacterial strain capable of exerting a bactericidal effect on pathogens associated with the occurrence of inflammation of the middle ear.

Not limited to any theory, the inventors believe that the effectiveness of the above bacterial strains in the prevention and treatment of inflammation of the middle ear may be associated with pathology of the disease. We believe that the mere presence of pathogens S. pneumoniae, N. influenzae and M. catarrhalis does not necessarily lead to an acute inflammation of the middle ear. Rather, the first must be a primary viral infection of the upper section of the respiratory tract, which somehow is not quite clear clicks the zoom, but probably related systemic immune response, violates the nasopharyngeal microbiota, allowing pathogenic bacteria to colonize the mucosa and cause the onset of inflammation of the middle ear. It is possible that the simultaneous stimulation of the systemic immune response and the number of non-pathogenic bacteriostatic and bactericidal bacteria in nasopharyngeal cavity can effectively prevent colonization of the mucosa of the nasopharynx pathogenic bacteria associated with the occurrence of inflammation of the middle ear.

Disclosure of inventions

In the present invention, the following words have definitions that need to be taken into account when reading and interpreting the description, examples and claims.

The following definitions given in article 1.2 of Directive 91/321/EEC of the European Commission of 14 may 1991 on the milk mixture for infants and mixtures for advanced and adopted in the present description.

“"Infant” is a child under the age of 12 months.

“The mixture for infants" - foods intended for special infant feeding in the first 4-6 months of life and of themselves meet the nutritional needs of this category of persons.

“The mixture for infants older than 4 months” - foods intended for special nutrition of infants older than 4 m the months and constituting the principal liquid component in gradually expanding the diet of this category of persons.

“Milk for young children” - milk drink, adapted to the specific nutritional needs of young children.

“Non-pathogenic bacterial strain is a bacterial strain that is not recognized as pathogenic for humans.

“The pathogens associated with the occurrence of inflammation of the middle ear is one or more from among Streptococcus pneumoniae, 't be typing Haemophilus influenzae and Moraxella catarrhalis.

“The young child” - a child aged 1 to 6 years (a small child).

All percentages are by weight, unless otherwise specified.

It should be borne in mind that used in the present invention the bacterial strains must be alive at the time of consumption. For this reason, the number of strains are expressed in colony forming units (CFU).

Bacterial strain capable of stimulating a systemic immune response, preferably presents Lactobacillus rhamnosus ADS 53103 or Lactobacillus rhamnosus CGMCC 1.3724. The strain L. rhamnosus ADS 53103 can be obtained commercially from the company Valio Shelter from Finland under the trade mark LGG®.

Bacteriostatic effect can be strains that are efficient producers of lactic acid. The ingestion of these bacteria, they produce lactic acid in sufficient quantity to have a significant local bacteriostatic effect the KTA near the mucosa of the nasopharynx, and thereby prevent the colonization of pathogenic bacteria. An example of such bacteria is Streptococcus thermophilus. A suitable strain of S. thermophilus is the one that sold under the trademark TN firm Christian Hansen from Denmark.

Some bacterial strains can have both bacteriostatic and bactericidal activity. Such strains are preferred for use in the present invention, since they can serve as a bacterial strain capable of exerting a bacteriostatic effects, and as a bacterial strain capable of exerting a bactericidal effects, thereby simplifying the complexity of production. Examples of such strains include Micrococcus varians MCV8 and Streptococcus salivarius DSM and DSM 13084 13085. The strain S. salivarius DSM 13084 can be obtained commercially from the company BLIS Technologies Limited from New Zealand under the brand K12.

Strains can be entered using the same media or can be entered separately.

Preferably the composition is a food composition that is consumed in liquid form and suitable for consumption by infants and young children. The composition may represent a complete formula type of formula for infants, a mixture of intermediate or milk for the young. As an alternative for the older subgroup of infants who young children, the composition may be a juice drink or other chilled or stable when stored beverage or soup, for example.

Preferably the nutritional composition according to the invention contains from 104up to 1012CFU/g of the composition (wet weight) of each strain.

The food composition according to the invention preferably further comprises at least one prebiotic in an amount of from 0.3 to 6%. A prebiotic is nevereverever food ingredient that beneficially affects the host organism by selective stimulation of growth and/or activity of certain bacteria or a limited number of bacteria in the colon and thus improves the health of the body. Such ingredients are neperevershenymy in the sense that they are not split and are not absorbed in the stomach or small intestine and therefore pass into the large intestine, where they are subjected to selective fermentation of beneficial bacteria. Examples of prebiotics include certain oligosaccharides, such as fructo-oligosaccharides (FOS) and galactooligosaccharides (GOS). You can use a combination of prebiotics, for example, 90% GOS and 10% short-chain FOS, as the product sold under the trademark Raftilose®or 10% of inulin as the product sold under the trademark Raftiline®. Especially preferred combination of prebiotics contains 70% of short-chain FOS and 30% inulin.

Now for example, we describe the overall composition of the mixture for infants according to the invention. The mixture contains a source of protein. We believe that the type of protein is not critical to the present invention, provided that you meet the minimum requirements in the content of essential amino acids and provides satisfactory growth. So, you can use protein sources based on whey, casein and their mixtures, as well as sources of protein, based on soy. As for whey protein, the protein source may be based on acid whey or sweet whey or mixtures thereof, and it may include α-lactalbumin and β-lactoglobulin in any desirable proportions.

Proteins can be intact or gidrolizovannykh or be a mixture of intact and hydrolysed proteins. It may be desirable application of partially hydrolyzed protein (degree of hydrolysis of from 2 to 20%), for example, for infants at risk of allergies to cow's milk. If you need hydrolysed proteins, the process of hydrolysis may be desirable and well known in this area by the way. For example, you can get hydrolyzed whey by enzymatic hydrolysis fraction of serum in one or several stages. If the fraction of serum, used as starting material, practically free from lactose, it turns out that white is subjected to significantly less blocking of lysine in the process of hydrolysis. This allows to reduce the degree of blocking of lysine with 15% of the total lysine content to less than 10% of the content of lysine, for example about 7% of the content of lysine, which greatly improves the nutritional value of the protein source.

The formula for babies of the present invention contains a source of hydrocarbons. You can use any sources of hydrocarbons that are typically included in the composition of the mixture for infants, such as lactose, sucrose, maltodextrin, starch and mixtures thereof, although the preferred source of hydrocarbons is lactose. Preferably, the sources of the hydrocarbons comprise from 35 to 65% of the total mixture supplying energy to birds.

The formula for babies of the present invention contains a source of lipids. Source of lipids can be any lipid or fat that is suitable for use in mixtures for infants. The preferred sources of lipids are palm olein, sunflower oil with high oleic acid safflower oil with high oleic acid content. You can also add essential fatty acids - linoleic and α-linolenic acid, as well as a small amount of oil containing a large number preobrazovannoe arachidonic acid and docosahexaenoic acids, such as fish oil or microbial oils. In General, the fat content preferably the leaves from 30 to 55% of the total mixture supplying energy to birds. The source of fat preferably has a ratio of fatty acid n-6/n-3 from 5:1 to 15:1, for example from 8:1 to 10:1.

Formula for infants should also contain all vitamins and minerals, which are considered essential in the daily diet, and significant from the point of view of food quantity. For some vitamins and minerals set out minimum requirements. Examples of minerals, vitamins and other nutrients optionally included in the composition of the mixture for infants include vitamin a, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, Inositol, Niacin, Biotin, Pantothenic acid, choline, calcium, phosphorus, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine and L-carnitine. Minerals are usually added in the form of salts. The presence and amount of specific minerals and other vitamins varies depending on the target population of infants.

If necessary, the mixture for infants may contain emulsifiers and stabilizers, such as soybean lecithin, esters of mono - and diglycerides with citric acid and other

The mixture for infants may optionally contain other substances which may have a beneficial effect, such as lactoferrin, nucleotides, nucleosides and other

Nakane is, the mixture should contain Lactobacillus rhamnosus ADS 53103 or Lactobacillus rhamnosus CGMCC 1.3724, Streptococcus salivarius DSM 13084 and Streptococcus thermophilus TH4®each in the range from 104up to 1012CFU/g of the composition (wet weight), and from 0.3 to 6% of a mixture of 90% GOS and 10% FOS.

The mixture can be obtained in any suitable way. For example, it can be obtained by mixing a protein, a carbohydrate source and a source of fat in the proper proportions. If you want, at this stage you can enable and emulsifiers. Vitamins and minerals can be added at this stage, but usually they are added later to avoid thermal decomposition. Lipophilic vitamins, emulsifiers, etc. may be dissolved in the fat before mixing. Then, to obtain a liquid mixture by mixing water is added, preferably subjected to reverse osmosis. Water temperature is usually from 50°C to 80°C, which contributes to the dispersion of the ingredients. To obtain a liquid mixture can be used commercially available thinners. Then the liquid mixture is homogenized, for example, in two stages.

The liquid mixture can then be subjected to heat treatment to reduce bacterial load by quickly heating it to a temperature in the range from 80°C to 150°C for from 5 seconds to 5 minutes, for example. This can be done by using steam, autoclave or heat is bennike, for example a plate heat exchanger.

Then, the liquid mixture can be cooled to a temperature from 60°C to 85°C, for example, by pulsed cooling. The liquid mixture may then be homogenized, for example, in two stages at 10-30 MPa in the first stage and 2-10 MPa in the second stage. Gomogenizirovannogo the mixture is then further cooled to add heat sensitive components, such as vitamins and minerals. At this stage it will be convenient to bring the pH and dry matter content of the homogenized mixture.

Gomogenizirovannogo the mixture is transferred to a suitable drying unit, such as a spray drier or freeze drier, and turned into powder. The powder should have a moisture content less than 5%.

Bacterial strains can be grown in any suitable way and prepare to add in the dry mixture for infants by the method of freeze drying or spray drying, for example. Alternatively, the specialist supplier, you can buy ready-bacterial drugs in the appropriate form to be added to such food products as a mixture for infants. Bacterial strains added to the mixture for infants by dry blending.

If the preferred liquid product, gomogenizirovannogo mixture can be subjected to sterilization, and then asepti the Eski fill it suitable containers, or fill it to capacity, and then autoclaved. After that, the bacterial strains should be put separately, ready for mixing with the liquid during use. For example, bacterial strains can be put in a separate bag or in a separate compartment of the packaging containing liquid.

In another embodiment the composition may be a Supplement that includes these strains in a quantity sufficient to achieve the desired effect in an individual. This form of application is more suitable for children older subgroups. Preferably the daily dose of bacterial strains ranges from 104up to 1012SOME. The number of bacteria included in the Supplement, you should choose depending on how this Supplement will apply. For example, if the additive is to be applied twice a day, each serving should contain from 102up to 106CFU of each bacterial strain. The additive may be in the form of tablets, capsules, lozenges or liquid, for example. The additive may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film-forming agents, encapsulating agents, materials of the shell, the connection matrix, coatings, emulsifiers, surface-active substances, soljubilizatory (oil, grease, wax, lecithin, and so is.), adsorbents, carriers, fillers, co active compounds, dispersing agents, wetting agents, processing AIDS (solvents), flowing agents, kusamakura agents, weighting materials, thickeners and gelling agents. The additive may also contain standard pharmaceutical additives and excipients, fillers and solvents, including water, gelatin of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum Arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifiers, buffers, lubricants, colorants, wetting agents, fillers and other

In addition, the additive may contain organic or inorganic substance carrier suitable for oral or enteral use, as well as vitamins, minerals, micronutrients and other nutritional trace elements in accordance with the recommendations of government bodies such as the USRDA.

Information confirming the possibility of carrying out the invention

Example 1

An example of the composition of the mixture for infants according to the present invention are presented below. This composition is only an illustration.

Nutrient 100 kcal1 liter
Energy (kcal)100670
Protein (g)1,8312,3
Fat (g)5,335,7
Linoleic acid (g)0,795,3
α-Linolenic acid (mg)101675
Lactose (g)11,274,7
Prebiotic (70% FOS, 30% inulin)0,644,3
Minerals (g)0,372,5
Na (mg)23150
K (mg)89590
Cl (mg)64430
CA (mg)62410
P (mg) 31210
Mg (mg)750
Mn (µg)850
Se (µg)213
Vitamin a (µg RE)105700
Vitamin D (µg)1,510
Vitamin E (mg TE)0,8of 5.4
Vitamin K1(g)854
Vitamin C (mg)1067
Vitamin b1(mg)0,070,47
Vitamin b2(mg)0,151,0
Niacin (mg)16,7
Vitamin b6(mg)0,0750,50
Folic acid (µg) 960
Pantothenic acid (mg)0,453
Vitamin b12(g)0,32
Biotin (µg)2,215
Choline (mg)1067
Fe (mg)1,28
I (g)15100
Cu (mg)0,060,4
Zn (mg)0,755
L. rhamnosus ADS 531032·107CFU/g powder
S. salivarius DSM 130842·107CFU/g powder
S. thermophilus TN2·107CFU/g powder

Example 2

In this example, the inhibitory effect of the composition according to the invention for some pathogens commonly associated with inflammation of the middle ear, srawniwa is carried out with the effect of composite parts themselves. Tested bacterial strains Lactobacillus rhamnosus ADS 53103 and Streptococcus salivarius DSM 13084, singly and in combination. Pathogenic strains, which evaluated the inhibitory activity of bacterial strains were represented by three different strains of Streptococcus pneumoniae and one strain of Alloiococcus otitidis. The range of inhibition of the test strains was determined by the method of deferred antagonism, as described previously (Tagg and Bannister, 1979). Briefly, the appropriate nutrient agar was inoculable bar culture of the test strain with a diameter of 1 cm After incubation macroscopic culture of bacteria was removed with the slide, and the remaining on the surface of the agar, the cells were destroyed by processing pairs of chloroform for 30 minutes Then the surface of the agar was blown with air for 30 minutes at a right angle to the line of the original bar culture was inoculable culture (18 h, 37°C) pathogenic strains from the broth Todd-Hewitt (THB, Difco). After incubation for 24 h at 37°C in an atmosphere of 5% CO2we measured the degree of inhibition of each pathogenic strain. The results are presented in the table below, which shows that all the tested pathogenic strains of a combination of Lactobacillus rhamnosus ADS 53103 and Streptococcus salivarius DSM 13084 had a stronger inhibitory effect than each of these strains separately.

Table
PathogenL. rhamnosus ATCC 53103S. salivarius DSM 13084S. pneumoniae RX1S. pneumoniae D39S. pneumoniae TIGR4A. otitidis NZRCC 3648
StrainSourceRRRRRR
inhibitorWednesday
53103BACA00000
13084BACA0171716
53103/13084 BACA201818
53103CHOC0
13084CHOC10
53103/13084CHOC15
BACA:blood agar with calcium
CHOC:chocolate blood agar
Source R= control culture

1. Nutrient composition profile for ctice or treatment of inflammation of the middle ear (otitis media), which includes non-pathogenic bacterial strain capable of stimulating a systemic immune response, non-pathogenic bacterial strain capable of exerting a bacteriostatic effects on pathogens associated with the occurrence of inflammation of the middle ear, and non-pathogenic bacterial strain capable of exerting a bactericidal effects on pathogens associated with the occurrence of inflammation of the middle ear, in which a bacterial strain capable of stimulating a systemic immune response, is a Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, bactericidal and bacteriostatic effects has the same bacterial strain selected from Micrococcus varians MCV8 or Streptococcus salivarius DSM 13084, each in an amount of from 104up to 1012CFU/g of the composition (wet weight).

2. The composition according to claim 1, which additionally contains Streptococcus thermophilus.

3. The composition according to claim 1 or 2, which further includes at least one prebiotic in an amount of 0.3 to 6% by weight of the composition.

4. The composition according to claim 1 or 2, representing a mix for infants.

5. The composition according to claim 1 or 2, representing a mix for infants older than 4 months.

6. The composition according to claim 1 or 2, representing the milk for young children.

7. The composition according to any one of claims 1 or 2, representing the dietary Supplement.



 

Same patents:

FIELD: veterinary science.

SUBSTANCE: composition comprises a source of lipids, containing fatty acids, also n-3 long-chain polyunsaturated fatty acide (LC PUFA-LC PUFA), prebiotic fibres, such as fructo-oligosaccharides, inulin, galacto-oligosaccharides, gum arabic and sialo-oligosaccharides or their mixture and a probiotic bacterial strain, in particular, Lactobacillus paracasei CNCMI-2116 or Lactobacillus rhamnosus ATCC 53103 or Bifidobacterium lactic CNCM 1-3446 and additionally contains n-6 long-chain polyunsaturated fatty acid in specified quantities. At the same time the mixture of prebiotic fibres may contain 40% - 60% of gum arabic, 10% - 20% of inulin and 30% - 40% of fructo-oligosaccharide.

EFFECT: invention makes it possible to compensate for growth retardation without use of synthetic hormones and increasing calorie consumption.

5 dwg, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and specifically to methods of recycling household wastes. The method involves removing inorganic impurities, grinding, mixing wastes with an organic additive containing a culture of microorganisms and composting to obtain organic fertiliser. The organic additive used is compost based on poultry droppings, which is taken in amount of 300-500 kg per ton of wastes, and microbial strains Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp. Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings.

EFFECT: simple process and low cost of processing household wastes.

1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to agriculture and can be used in processing cattle dung. The method involves formation of at least one pile of dung. Inoculating compost is added to the compost mass in amount of 10-15 kg/t. The compost mass is then moistened, biologically heated and periodically mixed. The inoculating compost used is compost based on poultry droppings and a consortium of microbial strains Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp.Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings.

EFFECT: high effectiveness of the process, simple preparation of inoculating compost and low consumption of microorganisms.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to bioconversion of poultry wastes and can be used in production of ecologically clean effective fertiliser for agricultural crops. The method involves successive layering of droppings and a water-absorbing organic material, forming at least one pile and adding microorganisms in liquid form in form of a suspension, stirring the mixture, biological heating and aerobic fermentation of the mixture. Aerobic fermentation of the mixture is carried out until temperature of the mixture naturally drops to 25-30°C. The microorganisms used are consortium of Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp. Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings.

EFFECT: cutting time for processing poultry droppings and improved quality of the biocompost.

2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to agriculture and can be used in processing organic wastes, particularly manure and turf to obtain organic fertiliser. The method involves layering manure and water-absorbing material - turf, adding compost followed by aerobic composting at 50-60% moisture content of the mixture. The compost used is inoculating compost based on poultry droppings and a consortium of microbial strains Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp. Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings. The inoculating compost is taken in weight ratio to the compost mixture of 1:20. Composting is carried out in piles.

EFFECT: simple process of making compost and obtaining compost with stable properties.

2 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: nutritive medium contains a dry concentrate of salmon fish milt decoction, microbiological agar, sodium chloride, glucose, yeast extract, activated carbon (powder), distilled water at preset quantities and 30% egg yolk emulsion introduced after the nutritive medium sterilisation in an amount of 50 ml/l of the sterile medium.

EFFECT: invention allows to reduce the period of identification of listeria lecithinase activity.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: method involves DNA recovery from a clinical specimen followed by the PCR procedure with using group-specific primers to ompA Chlamydia trachomatis gene sites; the electrophoresis analysis of the amplification products is used to type Chlamydia trachomatis by B, C genotype groups and an intermediate group that is followed by the PCR procedure with using a number of type-specific primers selected by the Chlamydia trachomatis genotype group typing values; and the electrophoresis analysis of the amplification products is used to type Chlamydia trachomatis by A, B, C, D, E, F, G, J, Ja, H and K genotypes.

EFFECT: invention provides the information value and simplification of Chlamydia trachomatis typing in the infection caused by any Chlamydia trachomatis genotype combinations.

2 ex

FIELD: agriculture.

SUBSTANCE: strain Streptomyces cellulosae WH9, deposited in CGMCC under the number NO.2167 and used to produce a microbial fertiliser. The strain Aspergillus versicolor WH13, deposited in CGMCC under the number NO.2171 and used to produce a microbial fertiliser. The microbial phosphate fertiliser contains a product of fermentation of a microbial composition containing the following four microorganisms: a strain Bacillus subtilis WH2 (CGMCC NO.0395.2), a strain Bacillus licheniformis WH4 (CGMCC NO.0395.4), a strain Streptomyces cellulosae WH9 and a strain Aspergillus versicolor WH13. Also the method is provided to manufacture the specified microbial phosphate fertiliser, where production of the specified microbial phosphate fertiliser may include using the ground phosphate rock containing 8%-12% P2O5.

EFFECT: improved properties of the strain.

8 cl, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: as antigens, vaccine contains a cell suspension of pure culture of E. coli colibacillosis, Str. pneumoniae streptococcus agents and rabbit hemorrhagic disease virus prepared by sampling the affected organs of dead rabbits of a local epizootic centre.

EFFECT: invention provides higher specificity and efficacy of the associated colibacillosis, streptococcus and rabbit viral hemorrhagic disease vaccine eliminating an adverse side effect on animals, and also can be used in research and manufacturing facilities involved in biological engineering.

1 tbl

FIELD: medicine.

SUBSTANCE: affected organs of dead rabbits from a local epizootic centre are sampled to prepare a suspension, and differential-diagnostic mediums are inoculated; pure-growth agents are recovered; separately, E. coli, Str. pneumoniae cultures are grown in a meat-peptone broth with glucose added to the concentration of 0.2% and titre 4-5 billion microbial cells in 1 cm3; then rabbits are infected with a hemorrhagic disease virus of the activity not less than 103.0 LD50/cm3, and liver of dead rabbits is used to prepare 10-15% suspension; thereafter the agent cultures are separately inactivated with formalin to the final concentration no more than 0.4% at temperature 37°C for 4 days or less; then the mixed inactivated cultures are added with an adjuvant presented by aluminium hydroxide gel in the amount of 20 vol %; the end product is thoroughly mixed before packing.

EFFECT: invention provides producing a harmless, high-immunogenic storage-stable vaccine.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is offered is application of 1-aminoalkylcyclohexane neramexane derivative or its salts for treating or preventing tinnitus, where treatment takes place within three to twelve months since presentation of tinnitus (subacute tinnitus) (versions), a related method of treating, and a pharmaceutical composition of the same purpose containing neramexane or its salts in a combination with an auxiliary pharmaceutical agent selected from antidepressants or anxiolytics, dopamine antagonists, alpha2delta-ligands and NK1 antagonists.

EFFECT: clinical effectiveness and safety before the stage of centralisation of the diseases, the patients appeared to show a good response on neramexane therapy.

21 cl, 1 dwg, 9 tbl

Ear hygiene drug // 2431486

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and veterinary science, and represents a drug for treating ear diseases in humans or animals, containing (a) an anti-infectious agent representing fluoroquinolone, (b) in an oily base encapsulated in a primary package for introduction of one single dose.

EFFECT: invention provides unexpectedly good adhesion to a surface of an acoustic meatus thereby it is actually impossible to shake it off from the acoustic meatus.

18 cl, 13 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical and cosmetic industry, in particular to otologic composition for dissolving, destruction and removal of earwax from ear canal. Otologic composition for dissolving, destruction and removal of earwax from ear canal, including extract of lapacho bark. Method of dissolving, destruction and removal of earwax in ear canal by means of otologic composition.

EFFECT: composition efficiently dissolves, destroys and removes earwax in ear canal.

7 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to otolaryngology, and can be used for treatment of sensorineural deafness of various etiology. For this purpose impact by pulse laser radiation through curved endoprobe is performed. Preliminarily carried out is anesthesis os lower and medial nasal ways and nasopharynx of irradiated side with 10% solution of lidocain by method of dispersion in direction from front to back through vestibule of nose. After that in lower nasal way introduced is polymer catheter, which fills common nasal way to the level of medial nasal turbinate. After that by channel, composed by medial nasal turbinate on one side and polymer catheter on the other side, introduced is endoprobe to the depth of contact with posterior wall, placing point of endoprobe irradiation at angle 25-45 degrees in horizontal plane 1.0-1.5 cm higher than pharyngeal orifice of auditory tube. Radiation is performed for 2-15 minutes in pulse mode with pulse power 5.5 W, pulse duration 60 ms, pulse frequency 6 Hz, with 30 sec pulse cycles.

EFFECT: method ensures stable improvement of auditory function, makes it possible to exclude injuries of mucosa and angiospasm, resulting in improvement of feeding and metabolic processes in cells of nerve fibres of auditory nerve.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to otolaryngology, and can be used for treatment of exudative otitis media. Method includes shunting of tympanic cavity with hollow prosthesis, introduction to patients in post-operation period of antibacterial medication of wide spectrum of action, mucolytic medication, endaural introduction of proteolytic medication, vasoconstrictive drops into nose. Additionally simultaneously, perorally introduced is preparation "Reaferon-EC-Lipint" in dose: children of 3-15 years 125000 IU daily 2 times per day for 7 days, children from 16-18 years - 250000 IU daily 2 times per day for 7 days. From eighth to tenth day of treatment patients continue to obtain peroral introduction of Reaferon-EC-Lipint in the following dose: children of 3-15 years 250000 IU daily 2 times per day for 3 days, children from 16-18 years -500000 IU daily 2 times per day for 3 days.

EFFECT: method makes it possible to increase efficiency of treatment of exudative otitis media in children and reduce number of disease recurrences.

1 tbl, 2 ex

Composition // 2398587

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicinal agents and concerns a composition for preparing a medicinal agent for local treatment of inflammations, containing at least, one glucocorticoid and N-chlorotaurine or N-chlorotaurine salt. There is also discovered a medicinal agent containing specified composition and application of the composition for preparing a medicated mixture for local treatment of inflammations.

EFFECT: lowered profile of (toxic) by-effects.

13 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine and concerns treatment and prevention of tinnitus induced by excitotoxic cochlear injury. That is ensured by administration of the pharmaceutical composition in therapeutically effective amount that contains arylcycloalkylamine, being a selective antagonist of NMDA-receptor.

EFFECT: choice of the selective antagonist of NMDA-receptor from arylcycloalkylamine group in excitotoxic cochlear injury allows treating or preventing tinnitus without any detrimental effect on hearing.

9 cl, 2 ex, 7 dwg

FIELD: medicine.

SUBSTANCE: present invention refers to pharmaceutics and medicine and concerns applications of phenothiazine derivative to produce a medical product used to prevent and/or treat hearing loss.

EFFECT: means ensures high clinical effectiveness.

20 cl, 1 ex

FIELD: medicine.

SUBSTANCE: application of vinpocetine is proposed for treatment of changes of retro-cochlear origin, related with epilepsy, characterised by inhibiting changes of amplitudes and latencies of late waves of hearing answer of brainstem (HAB), which accompany convulsions and for treatment of loss of hearing, characterised by inhibiting of hearing threshold increase, induced during convulsions.

EFFECT: vinpocetine inhibits all changes of HAB waves, which accompany cortical epileptic activity during ictal and post-ictal periods, also inhibits evident loss of hearing and changes of characteristics on EEG, induced by two convulsive agents, which differ by their mechanism of acting.

4 cl, 7 dwg, 6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly otolaryngology and treatment of chronic purulent medium otitis at reconstruction of middle ear deformities. It involves toilette and irrigation of newly formed acoustic meatus and tympanic cavity by Octenisept medicine solution at 1:5 ratio by attic cannula, followed byexposure to gas flow containing 0.1-0.3% of nitrogen monoxide at 18-20°C by Plazon device. Plazon handler nozzle is inserted to external acoustic meatus for 1.5-2 cm distance till physiological gorge. Afterwards the nozzle is exposed to both nasal cavity halves. Exposure is performed for 30 seconds once a day. Further Candibiotic medicine is applied onto tympanic cavity mucosa.

EFFECT: complete epithelisation of tympanic cavity, tympanic membrane coverage, reduced terms and enhanced efficiency of treatment due to improved drug absorption, normalised microcirculation, macrophage activation and fibroblast proliferation resulting from tympanic cavity mucosa preparation by Plazon device.

1 ex

FIELD: veterinary science.

SUBSTANCE: composition comprises a source of lipids, containing fatty acids, also n-3 long-chain polyunsaturated fatty acide (LC PUFA-LC PUFA), prebiotic fibres, such as fructo-oligosaccharides, inulin, galacto-oligosaccharides, gum arabic and sialo-oligosaccharides or their mixture and a probiotic bacterial strain, in particular, Lactobacillus paracasei CNCMI-2116 or Lactobacillus rhamnosus ATCC 53103 or Bifidobacterium lactic CNCM 1-3446 and additionally contains n-6 long-chain polyunsaturated fatty acid in specified quantities. At the same time the mixture of prebiotic fibres may contain 40% - 60% of gum arabic, 10% - 20% of inulin and 30% - 40% of fructo-oligosaccharide.

EFFECT: invention makes it possible to compensate for growth retardation without use of synthetic hormones and increasing calorie consumption.

5 dwg, 2 tbl, 2 ex

Up!